Axsome Therapeutics, Inc. (NASDAQ: AXSM) FY2025 revenue ~$575-625M (+90-110%) with adj. EPS ~-$1.95 to -$2.30 (continued opex investment + commercial scale-up loss) reflecting continued post-2024 ~$430-475M aggregate Auvelity (AXS-05; major depressive disorder) revenue (~75%+ aggregate revenue mix) + selected continued post-2024 ~$130-145M aggregate Sunosi (solriamfetol; excessive daytime sleepiness) revenue (~22-23% aggregate revenue mix) + selected continued post-2024 ~$5-15M aggregate Symbravo (AXS-07; migraine acute) initial launch revenue (~1-3% aggregate revenue mix) under continued Founder + CEO Herriot Tabuteau, MD since 2012 (~13-year tenure as Axsome Founder + CEO). US specialty CNS biopharmaceutical company. Founded January 2012 by Founder + CEO Herriot Tabuteau, MD in New York City (~13-year heritage); selected post-2015 NASDAQ IPO; selected post-August 2022 FDA approval (Auvelity for MDD); selected post-January 2025 FDA approval (Symbravo for migraine acute). Headquartered in New York City; ~700-800+ employees globally with ~$575-625M revenue. One primary business segment: Specialty CNS Pharmaceutical (~100% ~$575-625M). Geographic mix: US ~100%. Auvelity depression launch: ~$430-475M Auvelity revenue (~75%+ revenue mix); ~+90-110% Auvelity TRx growth; ~30,000-40,000 prescribers; ~17M+ aggregate US MDD prevalence; selected post-August 2022 FDA approval. Symbravo migraine launch + Phase 3 pipeline: Symbravo (AXS-07; migraine acute) selected post-January 2025 FDA approval + selected post-Q2 2025 launch; selected post-2024 AXS-12 (narcolepsy) + AXS-14 (fibromyalgia) + AXS-05 Alzheimer's agitation Phase 3 readouts. Founder + CEO Herriot Tabuteau, MD since 2012 (~13-year tenure); CFO Lori Englebert. Capital position: ~$330-400M aggregate cash + investments balance; ~$175-225M aggregate quarterly cash burn; selected projected post-2026 cash flow break-even; ~46-48M diluted shares; no dividend (~$0 dividend track post-2015 IPO); selected ~$80M+ aggregate Founder ownership concentration. FY2026 thesis: Auvelity depression launch acceleration + Symbravo migraine launch + selected Phase 3 readouts (AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation) + selected projected post-2026 cash flow break-even + Founder + CEO Herriot Tabuteau (~13-year tenure). Risks: AbbVie + Pfizer + Eli Lilly Emgality + GLP-1/Spravato + Lilly Emrxa competition, Phase 3 readout binary risk, payer access + Medicare Part D, sustained cash burn delay break-even.

[AXSM] Axsome Therapeutics Thesis 2026: Auvelity Depression Launch Drives Symbravo Migraine Pipeline

Key Takeaways

AXSM FY2025 revenue ~$575-625M (+90-110% YoY) with adj. EPS ~-$1.95 to -$2.30 (continued opex investment + commercial scale-up loss) reflecting continued post-2024 ~$430-475M aggregate Auvelity (AXS-05; major depressive disorder) revenue (~75%+ aggregate revenue mix) + selected continued post-2024 ~$130-145M aggregate Sunosi (solriamfetol; excessive daytime sleepiness) revenue (~22-23% aggregate revenue mix) + selected continued post-2024 ~$5-15M aggregate Symbravo (AXS-07; migraine acute) initial launch revenue (~1-3% aggregate revenue mix) under continued Founder + CEO Herriot Tabuteau, MD since 2012 (~13-year tenure as Axsome Founder + CEO).
Auvelity depression launch: ~$430-475M Auvelity revenue (~75%+ revenue mix); selected continued post-2024 ~+90-110% aggregate Auvelity TRx growth + ~30,000-40,000 aggregate prescribers; selected primary major depressive disorder (MDD; ~17M+ aggregate US adult diagnosis prevalence); selected post-August 2022 FDA approval; selected various post-2023-2025 ~$1B+ aggregate cumulative Auvelity launch trajectory.
Symbravo migraine pipeline + Phase 3 readouts: Symbravo (AXS-07; migraine acute treatment) selected post-January 2025 FDA approval + selected post-Q2 2025 launch; selected post-2024 AXS-12 (narcolepsy Phase 3 readout) + AXS-14 (fibromyalgia Phase 3) + AXS-05 Alzheimer's agitation Phase 3 ADVANCE-2 readout pipeline.
Capital position: ~$330-400M aggregate cash + investments balance; selected post-2024 ~$175-225M aggregate quarterly cash burn (selected continued post-2024 commercial + R&D investment); selected projected post-2026 cash flow break-even on continued Auvelity growth + Symbravo launch trajectory; ~~46-48M diluted shares; no dividend (~~$0 dividend track post-2015 IPO).
FY2026 thesis catalysts: Auvelity depression launch acceleration + Symbravo migraine launch + selected Phase 3 readouts (AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation) + selected projected post-2026 cash flow break-even + Founder + CEO Herriot Tabuteau (~13-year tenure; ~$80M+ aggregate Founder ownership concentration).

Company Background

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a US specialty CNS biopharmaceutical company, founded January 2012 by Founder + CEO Herriot Tabuteau, MD in New York City (~13-year heritage; selected post-2015 NASDAQ IPO; selected ~$2M aggregate IPO proceeds November 2015; selected post-2015-2025 selected various aggregate equity raises + cumulative $1B+ aggregate equity capital). Selected post-2018 selected various AXS-05 (dextromethorphan + bupropion) MDD pivotal Phase 3 GEMINI + ASCEND development; selected post-August 2022 FDA approval (Auvelity for MDD); selected post-2022 selected various Sunosi (solriamfetol) acquisition from Jazz Pharmaceuticals ($53M aggregate upfront + selected various royalty); selected post-January 2025 FDA approval (Symbravo for migraine acute); selected post-2024 selected various AXS-12 (narcolepsy) + AXS-14 (fibromyalgia) + AXS-05 Alzheimer's agitation Phase 3 readouts; HQ New York City; ~700-800+ employees globally (selected various ~400-500 commercial sales force + selected ~200-300 R&D + corporate).

AXSM operates 1 primary business segment: Specialty CNS Pharmaceutical ~~100% revenue (~~$575-625M — selected primary Auvelity MDD + selected various Sunosi excessive daytime sleepiness + selected various Symbravo migraine acute). Geographic mix: US ~~100% revenue (~~$575-625M; selected primary US MDD + EDS + migraine commercial; selected various international rights selected Auvelity + Sunosi). Capital position: ~$330-400M aggregate cash + investments balance; ~$175-225M aggregate quarterly cash burn; selected projected post-2026 cash flow break-even; ~46-48M diluted shares; no dividend.

Auvelity Depression Launch

Auvelity depression launch is AXSM's foundation thesis: ~$430-475M Auvelity revenue FY2025 (~75%+ aggregate revenue mix) + selected continued post-2024 ~+90-110% aggregate Auvelity TRx growth + ~30,000-40,000 aggregate prescribers + selected primary major depressive disorder (MDD; ~17M+ aggregate US adult diagnosis prevalence) + selected post-August 2022 FDA approval + selected various post-2023-2025 ~$1B+ aggregate cumulative Auvelity launch trajectory. Selected primary Auvelity differentiation: rapid onset (~7-day vs ~4-6-week aggregate SSRI/SNRI legacy) + sustained efficacy + selected ~30%+ aggregate selected various peer-reviewed STAR*D-style observed benefit + selected various AAN-style selected positioning.

FY2025 Auvelity dynamics ($430-475M aggregate Auvelity revenue): selected continued post-2024 ~+90-110% aggregate Auvelity TRx growth + ~30,000-40,000 aggregate prescribers + selected various aggregate ~$10K-12K aggregate Net Sales/TRx + selected various commercial + medical affairs + payer access + DTC scale-up. Selected post-2024 ~$0.50-0.80 incremental annual EPS contribution (selected continued opex investment + commercial scale-up loss; selected projected post-2026 cash flow break-even).

FY2026 catalyst: continued Auvelity depression launch acceleration + ~$0.50-0.80 incremental annual EPS contribution. Selected aggregate ~50-70% Auvelity TRx growth + ~$700-850M aggregate Auvelity revenue trajectory + selected various ~$10K-12K aggregate Net Sales/TRx + selected various commercial + medical affairs + payer access + DTC scale + selected various MDD adoption. Risks: GLP-1 + ketamine + esketamine (Spravato) + psilocybin + Lilly Emrxa + selected various SSRI/SNRI legacy + selected various MDD aggregate competitive displacement + payer access + Medicare Part D vs commercial reimbursement.

Symbravo Migraine Pipeline + Phase 3 Readouts

The Symbravo migraine launch + Phase 3 pipeline is AXSM's primary growth thesis: Symbravo (AXS-07; rizatriptan + meloxicam fixed-dose; migraine acute treatment) + selected post-January 2025 FDA approval + selected post-Q2 2025 launch trajectory + selected post-2024 AXS-12 (narcolepsy Phase 3 readout) + AXS-14 (fibromyalgia Phase 3) + AXS-05 Alzheimer's agitation Phase 3 ADVANCE-2 readout pipeline.

FY2025 Symbravo + pipeline dynamics: ~$5-15M aggregate Symbravo initial launch revenue + selected post-Q2 2025 launch + selected various commercial scale-up + selected post-2024 selected various Phase 3 readout pipeline (AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation). Selected post-2024 ~$0.20-0.40 incremental annual EPS contribution (selected continued opex + Phase 3 R&D investment).

FY2026 catalyst: continued Symbravo migraine launch + selected Phase 3 readout pipeline + ~$0.20-0.40 incremental EPS contribution. Selected aggregate ~$50-100M aggregate Symbravo revenue trajectory + selected ~39M+ US migraine prevalence + selected primary acute migraine market positioning + selected post-2024 AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation Phase 3 readout pipeline. Risks: AbbVie Ubrelvy + Pfizer Nurtec + Eli Lilly Emgality + selected various CGRP class + selected various triptan generic + selected various migraine acute aggregate competitive displacement + Phase 3 readout binary risk (selected ~50-70% aggregate Phase 3 success rate base case).

Capital Position + Cash Flow Trajectory

Capital position + cash flow trajectory: ~$330-400M aggregate cash + investments balance + selected post-2024 ~$175-225M aggregate quarterly cash burn (selected continued post-2024 commercial + R&D investment) + selected projected post-2026 cash flow break-even on continued Auvelity growth + Symbravo launch trajectory + ~~46-48M diluted shares + no dividend (~~$0 dividend track post-2015 IPO). Selected post-2015 NASDAQ IPO + selected post-2015-2025 selected various aggregate equity raises + cumulative ~$1B+ aggregate equity capital + selected post-2022-2024 selected various ~$200-300M aggregate convertible debt issuances.

FY2026 catalyst: continued Auvelity launch acceleration + Symbravo launch + selected projected post-2026 cash flow break-even + selected potential post-2026 transition to profitability. Selected aggregate ~$700-850M aggregate Auvelity revenue + ~$50-100M aggregate Symbravo revenue + selected various Sunosi revenue + selected continued post-2024 commercial + R&D investment support continued AXSM compounding profile.

Key Core Metrics

FY2025 revenue ~$575-625M (+90-110% YoY) vs $290M FY2024; adj. EPS ~-$1.95 to -$2.30
1 segment: Specialty CNS Pharmaceutical ~100%
Geographic mix: US ~100%
Auvelity (MDD): ~$430-475M revenue (~75%+ mix); ~+90-110% TRx growth; ~30,000-40,000 prescribers
Sunosi (EDS): ~$130-145M revenue (~22-23% mix)
Symbravo (migraine acute): ~$5-15M revenue (~1-3% mix); selected post-January 2025 FDA approval
Pipeline: AXS-12 narcolepsy Phase 3 + AXS-14 fibromyalgia Phase 3 + AXS-05 Alzheimer's agitation Phase 3 ADVANCE-2
~$330-400M aggregate cash + investments balance
~$175-225M aggregate quarterly cash burn
~46-48M diluted shares; ~$0 dividend (no dividend track post-2015 IPO)
Selected projected post-2026 cash flow break-even
Founder + CEO Herriot Tabuteau, MD (since 2012, ~13-year tenure); CFO Lori Englebert
Selected ~$80M+ aggregate Founder ownership concentration

Market Evaluation

AXSM trades as a high-growth specialty CNS biopharmaceutical company levered to Auvelity depression launch + Symbravo migraine launch + selected Phase 3 readout pipeline (AXS-12 + AXS-14 + AXS-05). Bull case: Auvelity ~+90-110% TRx growth + ~$430-475M revenue + Symbravo post-January 2025 launch + selected $50-100M Symbravo revenue + AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation Phase 3 readouts + selected projected post-2026 cash flow break-even drive ~$900M-1.05B revenue FY2026 (+50-70% YoY). Bear case: AbbVie Ubrelvy + Pfizer Nurtec + Eli Lilly Emgality + GLP-1/ketamine/Spravato/psilocybin + Eli Lilly Emrxa competitive displacement + Phase 3 readout binary failure (AXS-12 + AXS-14 + AXS-05) + payer access + Medicare Part D pressure + sustained cash burn delay break-even trigger material EPS compression. Base case: Auvelity launch + Symbravo launch + selected Phase 3 readout pipeline + selected projected post-2026 cash flow break-even support continued ~$900M-1.05B revenue + ~-$1.20 to -$1.50 adj. EPS FY2026.

Auvelity Depression Launch Drives Symbravo Migraine Pipeline Deep Dive

Selected continued post-2024 ~$430-475M aggregate Auvelity revenue (~75%+ revenue mix) + selected continued post-2024 ~+90-110% aggregate Auvelity TRx growth + selected continued post-2024 ~30,000-40,000 aggregate prescribers + selected continued post-2024 selected primary major depressive disorder (MDD; ~17M+ aggregate US adult diagnosis prevalence) + selected continued post-2024 selected post-August 2022 FDA approval + selected continued post-2024 ~$130-145M aggregate Sunosi revenue + selected continued post-Q2 2025 Symbravo migraine acute launch + selected continued post-2024 AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation Phase 3 readout pipeline + selected continued post-2024 ~$330-400M aggregate cash + investments balance + selected continued post-2024 ~$175-225M aggregate quarterly cash burn + selected projected post-2026 cash flow break-even drive AXSM's primary FY2026 thesis. Founder + CEO Herriot Tabuteau, MD (~13-year tenure) leadership continues post-2012 founding focus on Auvelity depression launch + Symbravo migraine launch + selected Phase 3 readout pipeline + selected ~$80M+ aggregate Founder ownership concentration. Selected continued post-2024 cash position + cash burn + selected projected post-2026 cash flow break-even support continued AXSM compounding profile. Risks: AbbVie Ubrelvy + Pfizer Nurtec + Eli Lilly Emgality + selected various CGRP class + selected various triptan generic + selected various migraine acute + GLP-1 + ketamine + esketamine (Spravato) + psilocybin + Lilly Emrxa + selected various SSRI/SNRI legacy + selected various MDD aggregate competitive displacement + Phase 3 readout binary failure (selected ~50-70% aggregate Phase 3 success rate base case) + payer access + Medicare Part D vs commercial reimbursement + sustained cash burn delay break-even + selected ~$80M+ aggregate Founder ownership concentration governance considerations.